Merck & Co. Inc. said on Thursday that it had received approval from the US Food and Drug Administration to market its asthma drug Singulair (montelukast) for treatment of seasonal allergic rhinitis.
The drug was approved late Tuesday by the FDA for relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older. The drug is sold in a 10-mg tablet form for adults and as a cherry chewable tablet in 4-mg or 5-mg strength for children ages 2 to 14 years.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!